A phase I/II trial of irinotecan–cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer

We conducted a phase I/II study in patients with advanced non-small-cell lung cancer (NSCLC) to increase the therapeutic index of the cisplatin–irinotecan combination by institution of an anti-late-diarrhoeal program (ADP). A total of 77 chemotherapy-naive patients with advanced NSCLC were enrolled....

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Y, Tsuduki, E, Izumi, S, Hojo, M, Kamimura, M, Naka, G, Kobayashi, K, Kudo, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361534/
https://www.ncbi.nlm.nih.gov/pubmed/16288302
http://dx.doi.org/10.1038/sj.bjc.6602866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361534/
https://www.ncbi.nlm.nih.gov/pubmed/16288302
http://dx.doi.org/10.1038/sj.bjc.6602866

Ejemplares similares